Company Profile

**Industry Sector:** Biotech Vaccine Discovery and Development

**Company Overview:** We use our proprietary virus-like particle (VLP) technology platform to discover highly active, yet safe, vaccines and then perform initial development. **Successful pre-clinical milestones** have been achieved with several pandemic influenza candidates (H5N1, H7N7, H1N1-1918) and we aim to initiate human clinical trials by year-end 2010.

The technology was invented by Dr. Galarza while a Principal Scientist at Wyeth. The company was founded in 2004 by Dr. J. Galarza based on a license from Wyeth with co-exclusivity on certain indications. TechnoVax benefits from over $5 million invested in the VLP technology platform since 1996.

**Target Market(s):**
Annual vaccine sales worldwide are projected to reach **$18 billion** and to increase 12% per year.

- Large and medium sized players, within the **Pharmaceutical Industry**, active or looking to enter the infectious diseases market.
- **Regional and local markets** with no current vaccine production capabilities seeking to take control of their national demand and supply.

Management

**Leadership:**

- **Jose M. Galarza,** President and CEO. 27 years of academic and industrial experience in the fields of virology and vaccine development.
- **George Martin,** Chief Technical Officer. Scientist Emeritus at the National Institutes of Health and former Senior Vice President for Scientific Affairs of Fibrogen, Inc.

**Scientific Advisory Board:**

- **Doris Bucher,** PhD, Professor Dept. of Microbiology and Immunology, New York Medical College.
- **Nathan Litman,** MD, Professor of Pediatrics, Albert Einstein College of Medicine, and Director of Pediatrics and Pediatric Infectious Diseases, Children’s Hospital at Montefiore.
- **Raphael P. Viscidi,** MD, Professor of Pediatrics at Johns Hopkins University School of Medicine.
- **Stephen Udem,** MD, PhD, internationally recognized virologist and vaccinologist and former Vice President of Wyeth vaccine division.

Key Value Drivers

**Technology:** TechnoVax has developed a novel way to produce highly immunogenic, non-infectious monovalent and polyvalent virus-like particle vaccines using a cell-based manufacturing system requiring no chemical inactivation. The technology is used to produce mass market vaccines for infectious diseases including influenza, respiratory syncytial virus (RSV), para-influenza virus (PIV) and other diseases such as Dengue, HIV and cancer.

**Competitive Advantage:** TechnoVax’s novel polyvalent VLP vaccines are produced in a high yield single manufacturing step utilizing a new, low investment, manufacturing process, reducing manufacturing time, steps and costs.

**Plan & Strategy:** Actively seeking **strategic partners** in our **target markets:**

- At regional level;
- Product centered;
- Project oriented;

We plan to develop and commercialize **safe and efficacious novel vaccines** with the most time and cost-effective manufacturing technology in order to unlock **significant commercial and competitive advantages.**

*Technology funded by the NIH grants and being commercialized under the NIH-CAP*

Product Pipeline and IP

- Patented technology and licensed by Wyeth with the option to sub-licence.
- Co-exclusive license with Wyeth for other respiratory virus targets (RSV, PIV, etc.)
- Additional patent applications protect proprietary VLP production for RSV, HIV as well as manufacturing methods.